Company Profiles

driven by the PitchBook Platform

Avitide

Description

Developer of a molecule-specific bio-pharmaceutical affinity purification technology designed to improve drug safety and establish biosimilarity. The company bio-pharmaceutical affinity purification technology focuses on purifying therapeutic proteins, enabling rapid development of chromatography resins via chemical synthesis, enabling their partners to achieve faster bioprocess development timelines, reduced program risk, predictable commercial scalability and lower cost of manufacturing for batch and continuous operations.

2012

Founded

PRIVATE

Status

11-50

Employees

Series E

Latest Deal Type

$12M

Latest Deal Amount

$28.5M

Total Amount Raised

Description

Developer of a molecule-specific bio-pharmaceutical affinity purification technology designed to improve drug safety and establish biosimilarity. The company bio-pharmaceutical affinity purification technology focuses on purifying therapeutic proteins, enabling rapid development of chromatography resins via chemical synthesis, enabling their partners to achieve faster bioprocess development timelines, reduced program risk, predictable commercial scalability and lower cost of manufacturing for batch and continuous operations.

Website:

www.avitide.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Primary Office

16 Cavendish Court Lebanon, NH 03766United States +1 (603) 965-2100
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Avitide's full profile, request a free trial.

    Avitide Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Avitide Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Avitide Investors (11)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Angeli ParviAngel GroupMinority000 0000000 0000
    Borealis VenturesVenture CapitalMinority000 0000000 0000
    Hoyoung HuhAngel (individual)Minority000 0000000 0000
    John BallardAngel (individual)Minority000 0000000 0000
    Mithril Capital ManagementVenture CapitalMinority000 0000000 0000
    Angeli Parvi Angel Group
    Borealis Ventures Venture Capital
    Hoyoung Huh Angel (individual)
    John Ballard Angel (individual)
    Mithril Capital Management Venture Capital

    Avitide Executive Team (6)

    NameTitleBoard
    Seat
    Contact
    Info
    Kevin Isett Ph.DCo-Founder & Chief Executive Officer
    Scott KennedyChief Financial Officer
    Warren Kett Ph.DCo-Founder & Chief Scientific Officer
    Jonathan ShellerCo-Founder & Director of Finance and Operations
    Dan FreymeyerHead, Business Development
    Kevin Isett Ph.D Co-Founder & Chief Executive Officer
    Scott Kennedy Chief Financial Officer
    Warren Kett Ph.D Co-Founder & Chief Scientific Officer
    Jonathan Sheller Co-Founder & Director of Finance and Operations
    Dan Freymeyer Head, Business Development

    Avitide Board Members (7)

    NameRepresentingRoleSinceContact
    Info
    Claudio Nessi Ph.DNeoMed ManagementManaging Partner000 0000
    Errik AndersonSelfCo-Founder & Board Member000 0000
    Ian RatcliffeSands Capital VenturesPartner000 0000
    Michael Ross Ph.DSV Health InvestorsManaging Partner, Biotechnology000 0000
    Phil Ferneau JDBorealis VenturesCo-Founder & Managing Director000 0000
    Claudio Nessi Ph.D Managing Partner NeoMed Management
    Errik Anderson Co-Founder & Board Member Self
    Ian Ratcliffe Partner Sands Capital Ventures
    Michael Ross Ph.D Managing Partner, Biotechnology SV Health Investors
    Phil Ferneau JD Co-Founder & Managing Director Borealis Ventures
    Request full access to PitchBook